Adolescents vaccine safety surveillance HPV vaccine safety surveillance data From January 2018 a new HPV vaccine, Gardasil9®, is being funded under the National Immunisation Program. AusVaxSafety is monitoring the safety of HPV vaccine in 11- to 14-year olds. The current reported event rates are consistent with what are expected according to the existing data. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here. Last updated 27/11/2020 78,717 Parents/carers responded to an SMS about their child’s health a few days after their HPV vaccinations. 91.3% reported no adverse events 91.3% reported no adverse events 8.7% reported any adverse event, including... 0.5% who reported taking their child to a doctor or emergency department in the days after vaccination.The adverse events they reported were similar to the types of adverse events reported overall 6,810 parents/carers reported one or more adverse events. The most commonly reported were: These symptoms are known to occur after vaccination. They are generally mild and short-lived. Influenza vaccine safety surveillance data Surveillance of 2020 influenza vaccine safety commenced from 9 April 2020. The current reported event rates are consistent with what are expected according to the existing data. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here. Last updated 04/09/2020 46,213 Parents/carers responded to an SMS about their child’s health a few days after their influenza vaccinations. 95.8% reported no adverse events 95.8% reported no adverse events 4.2% reported any adverse event, including... 0.2% who reported taking their child to a doctor or emergency department in the days after vaccination.The adverse events they reported were similar to the types of adverse events reported overall 1,956 parents/carers reported one or more adverse events. The most commonly reported were: These symptoms are known to occur after vaccination. They are generally mild and short-lived. Meningococcal vaccine safety surveillance data Surveillance of 2019 Men ACWY vaccine safety commenced from 1 April 2019. The current reported event rates are consistent with existing data on Men ACWY vaccines and no safety signals have been detected. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here. Last updated 27/11/2020 20,568 Parents/carers responded to an SMS about their child’s health a few days after their MenACWY vaccinations. 94.9% reported no adverse events 94.9% reported no adverse events 5.1% reported any adverse event, including... 0.4% who reported taking their child to a doctor or emergency department in the days after vaccination.The adverse events they reported were similar to the types of adverse events reported overall 1,058 parents/carers reported one or more adverse events. The most commonly reported were: These symptoms are known to occur after vaccination. They are generally mild and short-lived. Meningococcal B vaccine safety surveillance data From July 2020 a meningococcal B vaccine, Bexsero®, is being funded under the National Immunisation Program for Aboriginal and Torres Strait Islander children at 2, 4, and 12 months of age (with a catch up program for Aboriginal and Torres Strait Islander children aged under 2 years until 30 June 2023), and people of all ages with specified medical risk conditions that increase their risk of invasive meningococcal disease. AusVaxSafety is monitoring the safety of Bexsero vaccine. The current reported event rates are consistent with what are expected according to the existing data. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here. Last updated 20/11/2020 684 Parents/carers responded to an SMS about their child’s health a few days after their MenB vaccinations. 81.6% reported no adverse events 81.6% reported no adverse events 18.4% reported any adverse event, including... 1.0% who reported taking their child to a doctor or emergency department in the days after vaccination.The adverse events they reported were similar to the types of adverse events reported overall 126 parents/carers reported one or more adverse events. The most commonly reported were: These symptoms are known to occur after vaccination. They are generally mild and short-lived.
